-+ 0.00%
-+ 0.00%
-+ 0.00%

Agenus reports 48% estimated three-year survival in recurrent ovarian cancer trial of botensilimab plus balstilimab

PUBT·10/03/2026 14:52:01
Agenus reports 48% estimated three-year survival in recurrent ovarian cancer trial of botensilimab plus balstilimab
  • Agenus reported three-year follow-up results from its Phase 1b C-800-01 ovarian cancer cohort, presented at IGCS 2026 in Montréal.
  • Follow-up indicated durable survival in heavily pretreated recurrent ovarian cancer, including patients with platinum-resistant or refractory disease.
  • Some patients remained alive without ongoing therapy at the latest cut, supporting a potential long-lasting benefit in a subset of responders.
  • Safety profile remained consistent with prior experience, with no new safety signals or treatment-related deaths reported.
  • BOT and BAL remain investigational, with the update aimed at strengthening the case for broader development in hard-to-treat tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261003256338) on October 03, 2026, and is solely responsible for the information contained therein.